Why the study?
The study evaluated 30-day outcomes from the initial roll-in procedures performed at each site in the CLASP IID pivotal trial of the PASCAL system.
Does the PASCAL transcatheter valve repair system improve safety and functional outcomes in prohibitive surgical risk patients with DMR ≥3+?
Does the PASCAL transcatheter valve repair system improve safety and functional outcomes in prohibitive surgical risk patients with DMR ≥3+?
Early experience with the PASCAL transcatheter valve repair system demonstrates favorable 30-day safety and efficacy in prohibitive surgical risk patients with severe degenerative mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Favorable 30-day outcomes with first PASCAL experience in prohibitive-risk DMR; leaves open durability and comparative effectiveness.
Lim et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: